Oculus Innovative Sciences, Inc.: Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn(R) in the Topical

Oculus Innovative Sciences, Inc.: Oculus Innovative Sciences Receives European
 CE Mark for Use of Microcyn(R) in the Topical Treatment of Mild to Moderate
                                     Acne

 PETALUMA, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative
 Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs,
 manufactures and markets prescription and non-prescription products in 31
 countries, today announced receipt of the European CE Mark for the
 Microcyn®-based GramaDerm® Solution and GramaDerm® Hydrogel. Both products
 are intended for use in the topical treatment of mild to moderate acne and
 are designed to complement other acne treatments.

 The new CE Mark was issued by the European notified body, EMKI. The CE Mark
 is an indication that a medical device complies with the essential
 requirements of the medical devices directive (93/42/EEC) and that the
 device has been subjected to conformity assessment procedures. Receipt of
 the CE Mark will allow Oculus to market and sell the Microcyn-based
 GramaDerm Solution and GramaDerm Hydrogel in EU member countries that have
 adopted the medical devices directive without being subject to additional
 national regulations with regard to demonstration of performance and safety,
 although certain EU member countries may request or require additional
 performance and/or safety data from time to time, on a case-by case basis.

 "Securing the CE Mark for our acne products is just the beginning of Oculus'
 multiple product development initiatives in our continuing European growth
 strategy," said Bruce Thornton, Oculus executive vice president of
 international operations. "With CE Mark approval, our EU partnering process
 has picked up considerably. In addition, we anticipate announcing regulatory
 approvals and commercialization ofother Microcyn-based products, including
 those for new oral and advanced wound careindications, over the next few
 quarters."

 While a new drug application for Microcyn acne formulation has not yet been
 filed in the United States, a number of U.S. dermatologists have been using
 the Microcyn-based atopic dermatitis hydrogel since its introduction in
 early 2012.As permitted by law, some of these physicians have clinically
 evaluated the impact of Microcyn in the management of a wide range of
 dermatological afflictions including acne.

 "We've been successfully using a Microcyn-based hydrogel in my clinic for
 two years," said Dr. Rebecca Smith, a dermatologistat Fort Mill Dermatology
 in South Carolina. "I have seen promising secondary benefits of Microcyn in
 thereduction of inflammation and severity of acne outbreaks. Inlight of
 the European directive to reduce the use of topical antibiotics to
 minimizeresistance concerns, European dermatologists will be delighted with
 the news regardingGramaDerm's approval. We look forward to a similar
 product approval in the US in the future."

 In a study published in the Journal of Dermatological Treatment (April 2009)
 by Tirado-Sánchez, A. "Efficacy and Tolerance of superoxidized solution in
 the treatment of mild to moderate inflammatory acne," the Microcyn
 Technology, upon which the GramaDerm HydroGel is based, outperformed benzyl
 peroxide (a standard ingredient in many acne treatments) in the reduction of
 inflammatory lesions as a monotherapy associated with the treatment of
 acne.At the end of the 12-week study period, the percentage reduction in
 the number of inflammatory lesions from the initial baseline was 65% in the
 Microcyn arm versus 54% in the benzyl peroxide arm.The Microcyn product
 outperformed the benzyl peroxide, the general standard of care, but the
 difference was not statistically significant.However, the Microcyn
 technology has not, thus far, demonstrated any bacterial resistance and it
 tends to have an impeccable safety profile.

 Global Acne Market

 In a 2010 report issued by Research and Markets, it was indicated that the
 global acne market was worth $2.8 billion in 2009 and is estimated to reach
 revenues of $3.02 billion by 2016 at a Compound Annual Growth Rate (CAGR) of
 0.7%. The current market has several products which act on acne by targeting
 different etiologic factors involved in the development of acne. The acne
 therapeutics market is witnessing a shift towards combination products,
 using two or more effective acne treatments at one time. 

 The acne market is primarily genericised and is moderately served by the
 currently marketed drugs. The majority of the pipeline products of large
 pharmaceutical companies also consist of combination products with very few
 first-in-class molecules. With emerging me-too combination products in the
 pipeline that are not significantly different from the current
 monotherapies, the acne market awaits a blockbuster advance. Increases in
 the population in general and an increase in the prescription rate are
 estimated to sustain the acne market in the future.

 About Oculus Innovative Sciences

 Oculus Innovative Science is a global healthcare company that designs,
 manufactures and marketsprescription and non-prescription products in 31
 countries. The company's products are used to treat patients in
 surgical/advanced wound management, dermatology, women's health and animal
 health; addressing the unmet medical needs of these markets-while raising
 the standard ofpatient care and lowering overall healthcare costs. The
 company's headquarters are in Petaluma, California, with manufacturing
 operations in the United States and Latin America. More information can be
 found atwww.oculusis.com.

 Forward-Looking Statements

 Except for historical information herein,matters set forth in this press
 release are forward-looking within the meaning of the "safe harbor"
 provisions of the Private Securities Litigation Reform Act of 1995,
 including statements about the commercial and technology progress and
 futurefinancial performance of Oculus Innovative Sciences, Inc. and its
 subsidiaries (the "Company"). These forward-looking statements are
 identified by the use of words such as "anticipates,""believes," "expects,"
 and "intends,"among others. Forward-looking statements in this press
 release are subject to certain risks and uncertainties inherent in the
 Company's business that could cause actual results to vary,
 includingsuchrisks thatregulatory clinical and guideline developments may
 change,scientific data may not be sufficient to meet regulatory standards
 or receipt of required regulatory clearances or approvals,clinical results
 may not be replicated in actual patient settings,protection offered bythe
 Company'spatents and patent applications may be challenged, invalidated or
 circumvented by its competitors,the available market
 fortheCompany'sproducts will not be as large as expected,the
 Company'sproducts will not be able to penetrate one or more targeted
 markets,revenues will not be sufficient to fund further development and
 clinical studies, the Company may not meet itsfuture capital needs, and its
 ability to obtain additional funding, as well as uncertainties relative to
 varying product formulations and a multitude of diverse regulatory and
 marketing requirements in different countries and municipalities, and other
 risks detailed from time to time in the Company's filings with the
 Securities and Exchange Commission including the annual report on Form 10-K
 for theyear ended March 31, 2013. Oculus Innovative Sciences disclaims any
 obligation to update these forward-looking statements except as required by
 law.

 Oculus and Microcyn® Technology are trademarks or registered trademarks of
 Oculus Innovative Sciences, Inc. All other trademarks and service marks are
 the property of their respective owners.

CONTACT:

Media and Investor Contact:
        
Oculus Innovative Sciences, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Oculus Innovative Sciences, Inc. via Globenewswire
HUG#1758929
 
Press spacebar to pause and continue. Press esc to stop.